INVA - NASDAQ

Innoviva, Inc.

INVA·NASDAQ

$22.24

+2.5%

HealthcareBiotechnology

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.64B

EPS4.0200

P/E Ratio5.53

Earnings Date08/05/2026

425.13M

Revenue

19%

3Y+28.0%

5Y+26.0%

10Y+218.0%

271.17M

Net Income

1059%

3Y+27.0%

5Y+21.0%

10Y+355.0%

196.93M

Operating Cash Flow

3Y-2.0%

5Y-37.0%

10Y+223.0%

Innoviva, Inc. Profit Bridge

INVA · NASDAQ

Revenue & Cost of Sales

Revenue425.13M

Cost of Goods Sold (117.61M)

Gross Profit307.52M

Operating Expenses

Operating Expenses (143.77M)

Operating Income163.75M

Other Income & Taxes

Interest Expense (16.70M)

Other Income/Expense163.12M

Pretax Income326.86M

Income Tax (55.70M)

Net Income271.17M

Net Income

271.17M

Profitability Analysis

Gross Margin

72.3%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

38.5%

Outstanding operational efficiency. The company generates substantial profit from core operations.

Net Profit Margin

63.8%

Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.

Effective Tax Rate

17.0%

Moderate tax rate typical for most corporations. Represents standard tax burden on profits.

Profitability Insight

Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.

Innoviva, Inc. Income Statement

INVA • NASDAQ

Innoviva, Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
REVENUE
Revenue	425.1M	358.7M	310.5M	331.3M	391.9M	336.8M	261M	261M	217.2M	133.6M	53.9M	8.4M	4.8M	135.8M	24.5M	24.2M	24.4M	23.1M	22M	19.6M
GROSS PROFIT
Cost of Revenue	(117.6M)	(36.6M)	(42.6M)	(13.8M)	(0.0)	(0.0)	(0.0)	(0.0)	(1.4M)	(1.4M)	(2.6M)	(7.5M)	(9M)	(8.2M)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Gross Profit	307.5M	322.1M	267.8M	317.5M	391.9M	336.8M	261M	261M	215.9M	132.2M	51.3M	935K	-4.3M	127.6M	24.5M	24.2M	24.4M	23.1M	22M	19.6M
OPERATING INCOME
Operating Expenses	(143.8M)	(155.2M)	(153.9M)	(110.6M)	(16.8M)	(15.7M)	(14.7M)	(17M)	(25.5M)	(24.6M)	(22.4M)	(42.4M)	(173.6M)	(148.8M)	(134.2M)	(102.5M)	(104.6M)	(110.9M)	(190.6M)	(198.8M)
Selling, General & Administrative	(113.2M)	(115.7M)	(98.2M)	(63.5M)	(16.2M)	(13.9M)	(14.7M)	(17M)	(24.1M)	(23.2M)	(19.8M)	(34.9M)	(48.4M)	(30.9M)	(30.7M)	(27.5M)	(27.1M)	(28.9M)	(35.3M)	(32.2M)
Research & Development	(30.6M)	(13.7M)	(33.9M)	(41.4M)	(576K)	(1.8M)	(0.0)	(0.0)	(1.4M)	(1.4M)	(2.6M)	(7.5M)	(125.2M)	(117.9M)	(103.6M)	(75.1M)	(77.5M)	(82M)	(155.3M)	(166.6M)
Operating Income	163.7M	166.9M	113.9M	207M	375.1M	321.1M	246.4M	238.3M	183.6M	109M	31.6M	-33.9M	-168.9M	-13M	-109.7M	-78.3M	-81.4M	-93.2M	-168.6M	-179.2M
PRE-TAX INCOME
Interest Expense	(16.7M)	(22.2M)	(19.2M)	(15.8M)	(19.1M)	(18.3M)	(18.7M)	(24M)	(43.6M)	(52.4M)	(51.8M)	(36.9M)	(9.3M)	(6M)	(6M)	(6M)	(6.1M)	(5.7M)	(0.0)	(0.0)
Net Interest Income	4.4M	-3.1M	-3.3M	-9.4M	-17.2M	-16.8M	-13.1M	-22.3M	-42.3M	-51.8M	-51.5M	-36.3M	-8.6M	-5.5M	-5.6M	-5.5M	-3.9M	-439K	0.0	0.0
Other Expenses	(0.0)	(25.9M)	(21.8M)	(5.6M)	(0.0)	(0.0)	(0.0)	(0.0)	-7M	(2.4M)	(1.1M)	-3.3M	(6.7M)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Total Other Income Expenses Net	163.1M	-129.5M	80.2M	80M	70.2M	33.1M	-13.5M	-28M	-49.3M	-49.5M	-50.3M	-39.6M	-1.8M	-5.5M	-5.6M	-5.5M	-3.9M	-439K	8.6M	13.1M
Income Before Tax	326.9M	37.4M	194.1M	286.9M	445.3M	354.2M	232.9M	210.3M	134.3M	59.5M	-18.8M	-73.5M	-170.7M	-18.5M	-115.3M	-83.9M	-85.3M	-98.6M	-160M	-166M
NET INCOME
Income Tax Expense	(55.7M)	(14M)	(14.4M)	(66.7M)	(76.4M)	(60.4M)	(41.9M)	-196.1M	(0.0)	(0.0)	(0.0)	(0.0)	(1.8M)	(5.5M)	(415K)	(0.0)	(0.0)	(439K)	(0.0)	(0.0)
Net Income	271.2M	23.4M	179.7M	213.9M	265.9M	224.4M	157.3M	395.1M	134.1M	59.5M	-18.8M	-168.5M	-170.7M	-18.5M	-115.3M	-83.9M	-85.3M	-93.6M	-160M	-166M

SEC Filings

INVA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 18, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	March 27, 2026	December 31, 2025	2025	View Filing
DEF 14A DEF 14A 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 549 filings

Related Guides

Blog Categories

Continue your INVA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.